Roussel Uclaf

Aventis Pharma S.a.

Hoechst Marion Roussel

Aventis Pharma Limited

Jean-Luc Haesslein

Michel Fortin

Francois Clemence

Jacques Guillaume

Jean-Paul Vevert

Alain Corbier

Claude Oberlander

Branislav Musicki

Michel Klich

Patrick Laurin

Florence Bordon-Pallier

Anne-Marie Periers

Francedillaois Clemence

Fran&ccedil;ois Clemence

The invention relates to novel products of formula (I): in which:

Purine derivatives, method for preparing, pharmaceutical compositions and novel use

A compound of the formula wherein R is defined as in the specification, which compounds have an inhibitory effect vis-&#xe0;-vis cycline-dependent kinase proteins (cdk) and are endowed with antimitotic properties.

Derivatives of purine, their preparation process and pharmaceutical compositions containing them

Derivatives of purine having anti-proliferative properties and in particular, derivatives of purine endowed with an inhibitory effect vis-a-vis cycline-dependent kinase proteins i.e. abbreviated to 'cdk'.

Purine derivatives, preparation method and pharmaceutical compositions containing same

The use of purine derivatives of formula (I):in which:

Purine derivatives, preparation method and use as medicines

Aromatic amides, preparation method and application as medicines

20,21-dinor-eburnamenines

Compounds of the formula ##STR1## in all possible racemic, enantiomeric and diastereoisomeric forms and their non-toxic, pharmaceutically acceptable salts with acids and bases having antagonistic properties for angiotensin II receptors and a process and novel intermediates for their properties.

Nitrogenous bicycles

Novel N-substituted quinolines of the formula useful in the treatment of cardiovascular illnesses having an alteration in the vasomotricity and a process for their preparation.

N-substituted quinolines

Quinoline compounds

The bicyclic derivatives of pyridines of the formula ##STR1## and their non-toxic, pharmaceutically acceptable salts and a process and intermediates for their preparation which compounds are inhibitors of angiotensin II effects, particularly a vasoconstrictor activity.

Method for inhibiting vasoconstriction

Method of inhibiting angiotensin effects

Novel bicyclic compounds in all possible racemic, enantiomeric and diasteroisomeric forms of the formula ##STR1## having antagonistic properties for angiotensin II receptors and novel intermediates and process for their preparation.

Nitrogenous bicyclic derivatives substituted with benzyl

A compound in all racemic or optionally active forms selected from the group consisting of a compound of the formula ##STR1## where the substituents are defined as in the specification and their non-toxic, pharmaceutically acceptable acid addition salts having anti-anoxic activity and a novel process and intermediates for their preparation.

Growing community of inventors

Courtry, France

Jean-Luc Haesslein